Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04462328
Recruitment Status : Not yet recruiting
First Posted : July 8, 2020
Last Update Posted : October 19, 2020
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
BTK inhibition and checkpoint blockade are promising classes of therapy for central nervous system (CNS) lymphoma and have demonstrated efficacy with acceptable toxicity. A multidrug approach may carry a higher chance of durable efficacy in this aggressive disease that carries significant morbidity and mortality. Given the poor outcomes and limited options for patients who are not candidates for high-dose methotrexate, the investigators seek to evaluate the combination in this patient population.

Condition or disease Intervention/treatment Phase
Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma Drug: Durvalumab Drug: Acalabrutinib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study With Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary and Secondary Central Nervous System Lymphoma
Estimated Study Start Date : November 30, 2020
Estimated Primary Completion Date : February 28, 2022
Estimated Study Completion Date : May 31, 2026


Arm Intervention/treatment
Experimental: Phase I Dose Level 1: Durvalumab + Acalabruitinib
  • Acalabrutinib 100 mg twice per day by mouth on days 1-28
  • Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle
Drug: Durvalumab
Durvalumab will be administered over 60 minutes
Other Name: Imfinzi

Drug: Acalabrutinib
Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
Other Name: Calquence

Experimental: Phase I Dose Level 2: Durvalumab + Acalabruitinib
  • Acalabrutinib 200 mg twice per day by mouth on days 1-28
  • Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle
Drug: Durvalumab
Durvalumab will be administered over 60 minutes
Other Name: Imfinzi

Drug: Acalabrutinib
Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
Other Name: Calquence

Experimental: Expansion Cohort: Durvalumab + Acalabrutinib
  • Acalabrutinib 100 mg or 200 mg (depends on tolerable dose found in Phase I portion of study) twice per day by mouth on days 1-28
  • Durvalumab 1500 mg intravenous on day 1 of a 28 day cycle
Drug: Durvalumab
Durvalumab will be administered over 60 minutes
Other Name: Imfinzi

Drug: Acalabrutinib
Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
Other Name: Calquence




Primary Outcome Measures :
  1. Safe and tolerable dose of regimen [ Time Frame: Completion of first 12 weeks of treatment within phase I portion of study (estimated to be 14 months) ]
    • Defined as Dose Level 2 if 0 or 1 dose limiting toxicities (DLTs) are seen in patients at that dose level, or Dose Level 1 if 2+ DLTs are seen in Dose Level 2 but only 0 or 1 DLTs are seen in patients at Dose Level 1.
    • A DLT is defined as the occurrence of an adverse event (AE) that is at least possibly related to the investigational product (IP) or investigational regimen (IR)


Secondary Outcome Measures :
  1. Overall response rate (complete response (CR) + partial response (PR)) [ Time Frame: Through completion of treatment (estimated to be 6 months) ]
    • CR is defined as disappearance of all contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease, absence of any systemic corticosteroids prescribed to treat lymphoma (prophylactic steroid eye drops, topical steroids, corticosteroid antiemetics and steroids prescribed for non-disease reasons [e.g. asthma exacerbation, dermatologic or rheumatologic conditions] are allowed and not considered in the definition of CR), resolution of abnormal ocular findings on ophthalmological examination, negative CSF cytology/flow cytometry.
    • PR is defined as >50% reduction in contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease either with minor abnormalities on ophthalmological examination or normal ophthalmological examination OR disappearance of all contrast-enhancing CNS (brain and spine if latter abnormal at baseline) but only reduction of vitreous cells or retinal infiltrates or residual suspicious or positive CSF cytology.

  2. Duration of response [ Time Frame: Through 2 years post treatment (estimated to be 2 years and 6 months) ]
    -The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).

  3. Time to response [ Time Frame: Through completion of treatment (estimated to be 6 months) ]
    -Time to response is measured from the start of treatment until the time measurement criteria are met for first objective tumor response (CR or PR, whichever is first recorded).

  4. Progression-free survival (PFS) [ Time Frame: Through 2 years post treatment (estimated to be 2 years and 6 months) ]
    • PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
    • Progressive disease is defined as > 25% increase in contrast-enhancing CNS (brain and spine if latter abnormal at baseline) disease, appearance of any new, measurable (>/= 10mm) contrast-enhancing disease or recurrent or new ocular or CSF disease.
    • Progression free survival will include all patients with at least one response assessment. Patients will be censored for progression free survival and duration of response if alive and without disease progression at completion of follow-up period.

  5. Overall survival (OS) [ Time Frame: Until death (estimated to be 5 years and 6 months) ]
    • OS is defined as the duration of time from start of treatment to time of death.
    • All patients who receive treatment on study will be included in overall survival. Patients will be censored for overall survival is alive at last study data collection point (completion of follow-up).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented primary CNS lymphoma or secondary diffuse large B-cell lymphoma (DLBCL) isolated to the CNS with either:

    • Relapsed or refractory disease with at least 1 prior therapy OR
    • Ineligible for high dose methotrexate based therapy as determined by the treating physician, including previously untreated patients. Examples of medical conditions that for which a patient could be considered ineligible for high dose methotrexate include renal impairment, liver disease, heart failure or having ascites or effusions.
    • Patients with leptomeningeal disease only must have been previously treated with intrathecal therapy Note: For patients with history of histologically documented systemic DLBCL with CNS relapse, biopsy of the CNS lesion is recommended but not required.
  • Patients must have evaluable disease. This includes radiographic evidence of parenchymal disease or leptomeningeal enhancement or thickening, or disease detected in the CSF.

    *Patients with vitreous involvement alone are not eligible.

  • ECOG performance status of 0, 1, or 2. Patients with ECOG performance status of 3 are permitted if their performance status limitations are due to lymphoma in the opinion of the treating physician.
  • Participants must have adequate bone marrow and organ function shown by:

    • Absolute neutrophil count (ANC) ≥ 1.0 x 109/L
    • Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 7 days prior to study registration
    • Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR) < 2 times the upper limit of normal
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal
    • Serum bilirubin ≤ 1.5 times the upper limit of normal
    • Creatinine clearance > 30 mL/min calculated by the Cockcroft-Gault formula using actual body weight
  • Age ≥ 18 years of age
  • Body weight >30 kg
  • Participants must have a documented negative antibody to HIV
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • Female subjects of childbearing potential must have a negative pregnancy test no more than 3 days prior to the start of study treatment.
  • Able to understand and willing to sign an IRB approved written informed consent document. A legally authorized representative can consent on behalf of a patient who is able to understand the purpose and risk of the study but not able to provide a signature on the ICF and authorization to use PHI due to neurologic deficits (e.g. motor or language deficits)

Exclusion Criteria:

  • Concurrent use of other approved or investigational antineoplastic agents (with the exception of corticosteroids)
  • Participation in another clinical study with an investigational product during the 4 weeks prior to the first day of study treatment.
  • Prior chemotherapy or targeted small molecule therapy (or other therapy for CNS lymphoma) within 3 weeks prior to the first day of study treatment (or 5 half-lives (whichever is shorter)), or 2 weeks prior to the first day of study treatment for monoclonal antibodies

    *The patient must have recovered to baseline or ≤ grade 1 from prior toxicities of therapy with the exception of alopecia. Recovery to ≤ grade 2 neuropathy is permitted

  • External beam radiation therapy to the CNS within 14 days of the first day of study treatment.
  • Patient requires more than 8 mg of dexamethasone daily or the equivalent for control of CNS symptoms at the time of initiation of study therapy. Patients must taper off high dose corticosteroids for the control of CNS symptoms within 14 days after starting on study therapy.
  • History of intracranial hemorrhage or clinically significant stroke within 6 months prior to enrollment
  • Inability to swallow oral medications.
  • History of significant gastrointestinal disease that would limit absorption of oral medications.
  • Active concurrent malignancy requiring active therapy.
  • Prior therapy with a checkpoint inhibitor, including durvalumab.
  • Prior therapy with BTK inhibitor.
  • Warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Use of low molecular weight heparin and novel oral anticoagulants (eg. rivaroxaban, apixaban) is permitted if required.
  • Concurrent use of a moderate or strong inhibitor or inducer of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers prior to starting the study drug.

    *Study therapy may be started after 5-half-lives or 7 days (whichever is shorter) have surpassed since last administration of a strong or moderate CYP3A4 inducer/inhibitors.

  • Requires treatment with proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids any time prior to initiating study therapy are eligible for enrollment to this study.
  • Use of systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 10 mg/day of prednisone or the equivalent. This does not refer to patients on corticosteroids for CNS lymphoma symptoms. Participants must be off of immunosuppressant therapy (with the exception of steroids) for at least 14 days prior to the first day of study treatment. The items listed below are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Receipt of live attenuated vaccine within 30 days prior to the first day of study treatment. Note: Patients, if enrolled, should not receive live vaccine while receiving IP and up to 30 days after the last day of study treatment.
  • Suspicion of or confirmed progressive multifocal leukoencephalopathy
  • Active autoimmune disease (including autoimmune hemolytic anemia and immune thrombocytopenia purpura) requiring systemic treatment within the past two years (i.e. with the use of disease modifying agents, corticosteroids, or immunosuppressive drugs). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., due to Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone
    • Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroids replacement therapy for adrenal or pituitary insufficiency, etc.)
  • Significant medical diseases or conditions, as assessed by the investigator, that would substantially increase the risk to benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction in the past 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections,, severely immunocompromised state, and congestive heart failure, New York Heart Association Class III-IV.
  • Known bleeding diathesis (e.g. von Willebrand's disease), hemophilia, or active bleeding.
  • Known Human immunodeficiency virus (HIV) infection.
  • Known active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests and/or PCR.
  • History of invasive fungal infection, including invasive aspergillosis, or known active tuberculosis.
  • Major surgery ≤ 28 days prior to starting the trial treatment (or has not recovered from the side effects of such surgery) or plans to have surgery within 2 weeks of the first dose of the study drug.
  • Prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04462328


Contacts
Layout table for location contacts
Contact: Neha Mehta-Shah, M.D. 314-747-7510 mehta-n@wustl.edu

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Contact: Neha Mehta-shah, M.D.    314-747-7510    mehta-n@wustl.edu   
Principal Investigator: Neha Mehta-Shah, M.D.         
Sub-Investigator: Nancy Bartlett, M.D.         
Sub-Investigator: Mary-Kate Malecek, M.D.         
Principal Investigator: Fei Wan, Ph.D.         
Sub-Investigator: Maria Rosana Ponisio, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Neha Mehta-Shah, M.D. Washington University School of Medicine
Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT04462328    
Other Study ID Numbers: 202009139
First Posted: July 8, 2020    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasm Metastasis
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents